{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.0","upperLimit":"73.0","value":"53.4"},{"comment":"Not calculable/estimable due to insufficient number of events","groupId":"OG001","lowerLimit":"61.6","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as number of days from the date of first dose to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG000","title":"Main Cohort"},{"description":"Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.","id":"OG001","title":"Safety Expansion Cohort"}],"paramType":"MEDIAN","populationDescription":"All treated participants with available data","reportingStatus":"POSTED","timeFrame":"Up to the data cutoff date of 15 December 2020, approximately 7.5 years of follow-up","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}